See How It Works
Management Guidelines

2003 JNC 7 Report (BP reduction)
2010 AHA/ASA Guidelines (ICH)
2012 AHA/ASA Guidelines (aSAH)
2013 AHA/ASA Guidelines (AIS)

> See the recommendations

Dosing and Administration

Ready-to-use CARDENE® I.V.
(nicardipine hydrochloride)
offers convenient dosing
with rapid
or gradual
> Learn more

Roadmap to BP Control

Manage hypertension in
neuroemergencies from

> Take these critical steps


CARDENE® I.V. (nicardipine hydrochloride) Premixed Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or not desirable. For prolonged control of blood pressure, transfer patients to oral medication as soon as their clinical condition permits.1

Important Safety Information

CARDENE I.V. is contraindicated in patients with advanced aortic stenosis.

Hypotension and reflex tachycardia may potentially occur during treatment with CARDENE I.V.; therefore, close monitoring of blood pressure and heart rate is required. If unacceptable hypotension or tachycardia occurs, the infusion should be discontinued.

Slow titration of CARDENE I.V. is recommended in patients with heart failure or significant left ventricular dysfunction, particularly in combination with a beta-blocker.

Close monitoring of response to CARDENE I.V. is advised in patients with angina, heart failure, impaired hepatic function, or renal impairment.

To reduce the possibility of venous thrombosis, phlebitis, local irritation, and extravasation, administer CARDENE I.V. through large peripheral veins or central veins rather than arteries or small peripheral veins. If CARDENE I.V. is administered in a peripheral vein, to minimize the risk of venous irritation, change the site of infusion every 12 hours.

The most common adverse reactions (>3%) are headache, nausea/vomiting, hypotension, and tachycardia.

Please see full Prescribing Information.

References: 1. CARDENE I.V. (nicardipine hydrochloride) Premixed Injection Prescribing Information. Cary, NC: Cornerstone Therapeutics Inc.; 2013. 2. Bernard J-M, Pinaud M, Francois T, et al. Deliberate hypotension with nicardipine or nitroprusside during total hip arthroplasty. Anesth Analg. 1991;73(3):341-345. 3. The Joint Commission. Medication management. In: 2013 Hospital Accreditation Standards. Oakbrook Terrace, IL: The Joint Commission; 2013:MM1-MM24. 4. ASHP Council on Pharmacy Practice. ASHP guidelines: minimum standard for pharmacies in hospitals. In: Hawkins B, ed. Best Practices for Hospital & Health-System Pharmacy. 2012-2013 ed. Bethesda, MD: American Society of Health-System Pharmacists; 2012:453-463. 5. Marik, PE, Varon J. Hypertensive crises: challenges and management. Chest. 2007;131(6):1949-1962.

CARDENE® is a registered trademark of Chiesi USA, Inc. ©2014 Chiesi USA, Inc. All rights reserved.
Created in the USA. CI-Q312-13 Rev 4 Last updated 06/15.